BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:44 PM
 | 
Apr 21, 2009
 |  BC Extra  |  Top Story

Merck licenses mAbs from Medarex, MBL

Merck & Co. Inc. (NYSE:MRK) received exclusive, worldwide rights to develop and commercialize CDA-1 ( MDX-066/MBL-CDA1) and CDB-1 ( MDX-1388/MBL-CDB-1) from Medarex Inc. (NASDAQ:MEDX)...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >